NCT00048594

Brief Summary

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
800

participants targeted

Target at P75+ for phase_3 major-depressive-disorder

Timeline
Completed

Started Jan 2002

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 3, 2002

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

November 4, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 5, 2002

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 18, 2003

Completed
4 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 22, 2003

Completed
Last Updated

May 5, 2017

Status Verified

May 1, 2017

Enrollment Period

2 years

First QC Date

November 4, 2002

Last Update Submit

May 2, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total HAMD-17 score </= 10 after 10 weeks of treatment, time to relapse of depression over 6-10 months

    after 10 weeks of treatment and over 6-10 months

Secondary Outcomes (1)

  • CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; an HAMA total score change from week 10 at Month 6.

    Week 10 at Month 6

Interventions

Also known as: MK0869

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Patients with Major Depressive Disorder

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

MeSH Terms

Conditions

Depressive Disorder, Major

Interventions

Aprepitant

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

MorpholinesOxazinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Medical Monitor

    Merck Sharp & Dohme LLC

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 4, 2002

First Posted

November 5, 2002

Study Start

January 3, 2002

Primary Completion

December 18, 2003

Study Completion

December 22, 2003

Last Updated

May 5, 2017

Record last verified: 2017-05